Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INDUSTRY-FUNDED CME GUIDELINES ADVISE AGAINST FOCUS ON BRANDNAME

Executive Summary

INDUSTRY-FUNDED CME GUIDELINES ADVISE AGAINST FOCUS ON BRANDNAME products during educational meetings. The "Guidelines for Commercial Support of Continuing Medical Education" were adopted by the Accreditation Council for CME in mid-March and became council policy on May 1. They state: "Presentations must give a balance view of all therapeutic options. Use of generic names will contribute to this impartiality. If trade names are used, those of several companies should be used rather than that of a single sponsoring company." The Accreditation Council performs the accreditation process for the CME credits required of physicians, and also accredits and supervises the organizations conducting educational meetings. The council's sponsoring organizations include the American Medical Association and groups representing state licensure boards and professional certification societies. The new guidelines were developed by the Joint Task Force on Pharmaceutical Industry/CME Provider Collaboration, which was coordinated by AMA and had industry members ("The Pink Sheet" Sept. 24, p. 18). Interest in the guidelines intensified with Sen. Kennedy's (D-Mass.) investigation into industry promotional practices, including sponsorship of medical symposia. The guidelines also advise that the "ultimate decision regarding funding arrangements for CME activities must be the responsibility of the accredited sponsor. Funds from commercial sources should be in the form of an educational grant made payable to the accredited sponsor for the support of the programming." The guidance adds that "reasonable honoraria and reimbursement for out-of-pocket expenses for faculty is customary and proper. Commercial support must be acknowledged in printed announcements and brochures; however, reference must not be made to specific products." The guidelines also direct that commercially supported social events should "not compete with nor take precedence over" educational sessions; it is "not permissible" to pay for personal travel expenses or honoraria for attendees; and all accredited sponsors should develop and adhere to a conflict of interest policy. Overall, the guidelines advise the accredited sponsors that they are "responsible for the content, quality and scientific integrity of all CME activities certified for credit." The guidelines are prefaced by a statement that CME sponsors "often receive financial and other support from non-accredited organizations. Such support can contribute to the quality of CME activities." The accredited sponsor, however, must ensure that the session is geared to enhancing the physician's patient care ability. AMA is implementing its own standards related to gifts from industry. Those guidelines state that gifts are permissible only if they are not "substantial" and do not have "strings attached" such as a tie to prescribing practices; that personal travel expenses to meetings should not be accepted; and that companies may make a contribution to help defray the general costs of an educational meeting providing the sponsorship is disclosed ("The Pink Sheet" Feb. 18, T&G-2).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS019016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel